Study for the effect of Danlou tablet on gut microbiota of CHD patients and its metabolomics

Phase 4

• Conditions: coronary heart disease

• Registration Number: ITMCTR1900002563
• Lead Sponsor: Traditional Chinese Medicine Hospital of Tailai County, Qiqihar City, Heilongjiang Province

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Aged between 40-85 years;
2. Meets the diagnostic criteria for stable coronary heart disease;
3. singed the consent form.

Exclusion Criteria

1. Combined with Congenital heart disease, rheumatic heart disease, unstable angina pectoris;
2. Combined with Valvular disease, suspected major artery dissection, arrhythmia, acute heart failure, moderate to severe pulmonary hypertension, acute pulmonary embolism and other serious cardiopulmonary dysfunction;
3. Combined with Severe liver and kidney dysfunction, immune diseases;
4. Combined with acute infection;
5. Patients who used antibiotics, other lipid-lowering and blood-glucose lowering drugs and other Chinese medicines before 2 weeks and during the experiment;
6. Involuntary patients, poor compliance;
7. Participated in other clinical trials.

Study & Design

• Study Type: Basic Science
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Angina pectoris;LPS, TMAO;TC TG HDL LDL;IL-1ß, IL-6, IL-10, TNF-alpha;echocardiography;gut microbiota;Blood glucose;Electrocardiogram;Apolipoprotein A1 and B;Symptoms of traditional Chinese medicine;Hematology and stool metabolomics;